

References for Presentation:
Improving Immune System Function by Targeting
Periodontitis? (Only on potential of periodontitis to increase risk
for complications of COVID-19)
Date of compilation: July 27, 2020



1. Awano S, et al. Oral health and mortality risk from pneumonia in the elderly. *J Dent Res* 2008; 87:334-339.
2. Beusekom MV. Old age, sepsis tied to poor COVID-19 outcomes, death. Center for Infectious Disease Research and Policy. CIDRP News. Mar 10, 2020; www.cidrap.umn.edu/news-perspective/2020/03/old-age-sepsis-tied-poor-covid-19-outcomes-death. Accessed July 25, 2020.
3. Cox MJ, Loman N, Bogaert D, et al. Co-infections: potentially lethal and unexplored in COVID-19. Correspondence. *Lancet* 2020. [https://www.thelancet.com/pdfs/journals/lanmic/PIIS2666-5247\(20\)30057-4.pdf](https://www.thelancet.com/pdfs/journals/lanmic/PIIS2666-5247(20)30057-4.pdf). Accessed on July 24, 2020.
4. Daep CA, Novak EA, Lamont RJ, et al. Structural dissection and in vivo effectiveness of a peptide inhibitor of *Porphyromonas gingivalis* adherence to *Streptococcus gordonii*. *Infect Immun* 2011; 79:67-74.
5. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. *Nature Rev Microbiol* 2010; 8:481-490.
6. Farrugia C, Stafford GP, Potempa J, et al. Mechanisms of vascular damage by systemic dissemination of the oral pathogen *Porphyromonas gingivalis*. *FEBS J*. Accepted Author Manuscript. Doi: 10.1111.
7. Finegold SM. Aspiration pneumonia. *Rev Infect Dis* 1991; 13(Suppl 9):S737-742.
8. Gagnon A, Miller MS, Hallman SA, et al. Age-specific mortality during the 1918 influenza pandemic: unravelling the mystery of high young adult mortality. *PLOS ONE*. 2013; 8(8):e69586.
9. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. *Nat Rev Immunol* 2015; 15(1):30-44.
10. Hajishengallis G. The inflammophilic character of the periodontitis-associated microbiota. *Mol Oral Microbiol* 2014; 29(6):248-257.
11. Hayata M, Watanabe N, Tamura M. The Periodontopathic Bacterium *Fusobacterium nucleatum* Induced Proinflammatory Cytokine Production by Human Respiratory Epithelial Cell Lines and in the Lower Respiratory Organs in Mice. *Cell Physiol Biochem* 2019;53:49-61.
12. Heo SM, Haase EM, Lesse AJ, et al. Genetic relationships between respiratory pathogens isolated from dental plaque and bronchoalveolar lavage fluid from patients in the intensive care unit undergoing mechanical ventilation. *Clin Infect Dis* 2008; 47:1562-1570.

13. Kesavalu L, Sabapathi S, Bakthavatchalu V, et al. Rat model of polymicrobial infection, immunity, and alveolar bone resorption in periodontal disease. *Infect Immun* 2007; 75:1704-1712.
14. Kimizuka R, Kato T, Ishihara K, et al. Mixed infections with *Porphyromonas gingivalis* and *Treponema denticola* cause excessive inflammatory responses in a mouse pneumonia model compared with mono-infections. *Microbes Infect* 2003; 5:1357-1362.
15. Lamont RJ, Chan A, Belton C, et al. *Porphyromonas gingivalis* Invasion of Gingival Epithelial Cells. *Infection and Immunity* 1995; 63(10):3878-85.
16. Liu Q, Zhou Y, Yang Z. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cellular and Molecular Immunology* 13(1):3-10.
17. MacIntyre CR, Chughtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. *BMC Infectious Diseases* 2018; 18:637.
18. Madhi SA, Klugman KP. A role for *Streptococcus pneumoniae* in virus- associated pneumonia. *Nat Med* 2004; 10:811-3.
19. Orth RK, O'Brien-Simpson NM, Dashper SG, et al. Synergistic virulence of *Porphyromonas gingivalis* and *Treponema denticola* in a murine periodontitis model. *Mol Oral Microbiol* 2011; 26:229-240.
20. Paju S, Scannapieco FA. Oral biofilms, periodontitis, and pulmonary infections. *Oral Dis* 2007; 13:508-512.
21. Peng CH, Yang YS, Chan KC, et al. Periodontal Treatment and the Risks of Cardiovascular Disease in Patients with Type 2 Diabetes: A Retrospective Cohort Study. *Intern Med* 2017; 56:1015-1021.
22. Polak D, Wilensky A, Shapira L, et al. Mouse model of experimental periodontitis induced by *Porphyromonas gingivalis*/ *Fusobacterium nucleatum* infection: bone loss and host response. *J Clin Periodontol* 2009; 36:406-410.
23. Preshaw PM, Taylor JJ, Jaedicke KM, et al. Treatment of periodontitis reduces systemic inflammation in type 2 diabetes. *J Clin Periodontol* 2020; 47(6) 737-746.
24. Rosenwald MS. History's deadliest pandemics, from ancient Rome to modern America. *Washington Post*. Archived from the original on 7 April 2020.
25. Saito A, Kokubu E, Inagaki S, et al. *Porphyromonas gingivalis* entry into gingival epithelial cells modulated by *Fusobacterium nucleatum* is dependent on lipid rafts. *Microb Pathog* 2012; 53(5-6):234-242.
26. Scannapieco FA, Genco R J. Association of periodontal infections with atherosclerotic and pulmonary diseases. *J Periodontal Res* 1999; 34:340–345.
27. Scannapieco FA. Role of Oral Bacteria in Respiratory Infection. *J Periodontol* 1999; 70: 793-802.
28. Schacht O. COVID-19 Patients Need to Be Tested for Bacteria and Fungi, Not Just the Coronavirus. *Scientific American*; April 16, 2020. www.blogs.scientificamerican.com/observations/covid-19-patients-need-to-be-tested-for-bacteria-and-fungi-not-just-the-coronavirus/. Accessed July 25, 2020.

29. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? *Nature Reviews Immunology* 2020; 20:271.
30. Shi Z, Gewirtz AT. Together Forever: Bacterial-Viral Interactions in Infection and Immunity. *Viruses* 2018; 10,122.
31. Tan KH, Seers CA, Dashper SG, et al. *Porphyromonas gingivalis* and *Treponema denticola* exhibit metabolic symbioses. *PLoS Pathog* 2014; 10:e1003955.
32. Tay MZ, Poh CM, Rénia L, et al. The Trinity of COVID-19: Immunity, Inflammation and Intervention. *Nat Rev Immunol* 2020; 20: 363-374.
33. Wadia, R. Periodontal treatment and systemic inflammation. *Br Dent J* 2020; 228:761.
34. Wong JP; Viswanathan S, Wang M, et. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Medicinal Chemistry* 2017; 9 (2):169-178.
35. Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180(7):934-943.
36. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective study. *Lancet* 2020; 395: 1054-1062.